The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome
Abstract
CONTEXT: Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined. OBJECTIVE: To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia. DESIGN, SETTING, AND PATIENTS: Positron emission tomography (PET) studies of [(18)F]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000. MAIN OUTCOME MEASURES: Regional distribution of [(18)F]fluorodeoxyglucose in each patient, classified by criteria established a priori as positive or negative for presence of a progressive neurodegenerative disease in general and of Alzheimer disease (AD) specifically, compared with results of longitudinal or neuropathologic analyses. RESULTS: Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). Among patients with neuropathologically based diagnoses, PET identified patients with AD and patients with any neurodegenerative disease with a sensitivity of 94% and specificities of 73% and 78%, respectively. The negative likelihood ratio of experiencing a progressive vs nonprogressive course over the several years following a single negative brain PET scan was 0.10 (95% confidence interval, 0.06-0.16), and the initial pattern of cerebral metabolism was significantly associated with the subsequent course of progression overall (P<.001). CONCLUSION: In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general. A negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Likelihood ratios with confidence: Sample size estimation for diagnostic test studies
Simel, D. L., Samsa, G. P., & Matchar, D. B. (1991) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(91)90128-v · Cited by 932
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Self-citationFRACKOWIAK, R. S. J., POZZILLI, C., LEGG, N. J., BOULAY, G. H., MARSHALL, J., LENZI, G. L., & JONES, T. (1981) · Brain · doi:10.1093/brain/104.4.753 · Cited by 683
The US economic and social costs of Alzheimer's disease revisited.
Ernst, R. L., & Hay, J. W. (1994) · American Journal of Public Health · doi:10.2105/ajph.84.8.1261 · Cited by 588
Alzheimer's disease: Focal cortical changes shown by positron emission tomography
Foster, N. L., Chase, T. N., Fedio, P., Patronas, N. J., Brooks, R. A., & Chiro, G. D. (1983) · Neurology · doi:10.1212/wnl.33.8.961 · Cited by 540
FDG PET imaging in patients with pathologically verified dementia.
Hoffman, J. M., Welsh-Bohmer, K. A., Hanson, M., Crain, B. J., Hulette, C. M., Earl, N., & Coleman, R. E. (2000) · PubMed · Cited by 399
Self-citationEstimated Prevalence of Alzheimer's Disease in the United States
Evans, D. A. (1990) · The Milbank Quarterly · doi:10.2307/3350099 · Cited by 357
FDG PET and Differential Diagnosis of Dementia
Herholz, K. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199505000-00004 · Cited by 200
Positron Emission Tomography in the Study of Aging and Senile Dementia
Ferris, S. H., de Leon, M. J., Wolf, A. P., Farkas, T., Christman, D. R., Reisberg, B., Fowler, J. S., MacGregor, R., Goldman, A., George, A. E., et al. (1980) · Neurobiology of Aging · doi:10.1016/0197-4580(80)90005-6 · Cited by 198
Self-citationSmith, G. S. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530350056020 · Cited by 178
Chui, H., & Zhang, Q. (1997) · Neurology · doi:10.1212/wnl.49.4.925 · Cited by 165
Current Concepts in the Pathogenesis of Alzheimer’s Disease
Carr, D. B., Goate, A., Phil, D., & Morris, J. C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00262-3 · Cited by 158
Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease
Herholz, K., Nordberg, A. K., Salmon, É., Perani, D., Kessler, J., Mielke, R., Halber, M., Jelić, V., Almkvist, O., Collette, F., et al. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017196 · Cited by 139
Self-citationDifferential diagnosis of Alzheimer's disease with PET.
Salmon, É., Sadzot, B., Maquet, P., Degueldre, C., Lemaire, C. F., Rigo, P., Comar, D., & Franck, G. (1994) · PubMed · Cited by 138
Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease
Mielke, R., Schröder, R., Fink, G. R., Kessler, J., Herholz, K., & Heiß, W.-D. (1996) · Acta Neuropathologica · doi:10.1007/s004010050410 · Cited by 111
Self-citationThe use of positron emission tomography in the clinical assessment of dementia
Mazziotta, J. C., Frackowiak, R. S. J., & Phelps, M. E. (1992) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(05)80118-7 · Cited by 95
Self-citationSilverman, D. H. S., Small, G. W., & Phelps, M. E. (1999) · Clinical Positron Imaging · doi:10.1016/s1095-0397(99)00020-5 · Cited by 92
Self-citationPietrini, P., Alexander, G. E., Furey, M. L., Hampel, H. J., & Guazzelli, M. (2000) · International Journal of Psychophysiology · doi:10.1016/s0167-8760(00)00097-0 · Cited by 66
Self-citationPositron emission computed tomography in the diagnosis of dementia.
Benson, D. F., Kuhl, D. E., Phelps, M. E., Cummings, J. L., & Tsai, S.-F. (1981) · PubMed · Cited by 56
Self-citation
Cited by
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationAlzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Metadata
- Authors
- Silverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., Schapiro, M. B., Jagust, W. J., Hoffman, J. M., Welsh-Bohmer, K. A., Alavi, A., Clark, C. M., Salmon, E., de Leon, M. J., Mielke, R., Cummings, J. L., Kowell, A. P., Gambhir, S. S., Hoh, C. K., & Phelps, M. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-11-07
- Volume
- 286
- Issue
- 17
- Pages
- 2120
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2146272386
- Cited by
- 951
- References
- 21
- FWCI
- 22.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.